Bellerophon Therapeuticsincis A Clinical Stage Biotherapeutics Company Based In Warrennew Jerseyfounded In 2009The Company Focuses On Developing Therapies For Cardiopulmonary And Cardiac Diseasesit Operates At The Intersection Of Drugs And Medical Devicesaiming To Address Unmet Medical Needsbellerophon Employs Around 18 Staff And Is Led By Ceo Craig Jalbert The Company S Primary Innovation Is The Inopulseaplatforma Proprietary System For Delivering Pulsatile Nitric Oxide To Treat Pulmonary Hypertension Across Various Conditionsbellerophon Is Conducting Clinical Trials For Inopulse In Fibrotic Interstitial Lung Diseasechronic Obstructive Pulmonary Diseasesarcoidosisand High Altitude Pulmonary Edemaadditionallythe Company Is Developing The Bioabsorbable Cardiac Matrixbcm An Injectable Device Aimed At Preventing Cardiac Remodeling After A Heart Attackbellerophon Holds Exclusive Global Rights For Inopulse And Has Secured A License For Bcm From Biolinerx
